Cargando…

Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells

PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusovici, Raluca, Sakhalkar, Monali, Chalam, Kakarla V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/
https://www.ncbi.nlm.nih.gov/pubmed/22219629
_version_ 1782220046390525952
author Rusovici, Raluca
Sakhalkar, Monali
Chalam, Kakarla V.
author_facet Rusovici, Raluca
Sakhalkar, Monali
Chalam, Kakarla V.
author_sort Rusovici, Raluca
collection PubMed
description PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and ameliorates neovascularization after intracameral administration. However, the safety of intracameral administration of Bevacizumab and dose–dependent toxicity on corneal endothelial cells has not been established. METHODS: Bovine corneal endothelial (BCE) cells were treated with VEGF (50 ng/ml) and/or Bevacizumab (0.1–2 mg/ml) for 72 h. Cell proliferation was measured with the water soluble tetrazolium salts (WST-1) assay. Morphological changes were recorded by bright-field microscopy of cells. Cytotoxicity in response to Bevacizumab was evaluated by trypan blue exclusion, as well as annexin V/propidium iodide (PI) staining. RESULTS: Bevacizumab was not cytotoxic at the concentrations tested and the percentage of Bevacizumab-treated cells staining positively for both PI and Annexin V was less than 1%. The anti-proliferative effects of Bevacizumab on BCE cells were dose-dependent; a dose of 1.5 mg/ml or 2 mg/ml produced a 33% (p=0.005) or 47% (p=0.001) decrease in cell proliferation compared to controls. Similar results were obtained in cells treated with a combination of Bevacizumab and VEGF. VEGF (50 ng/ml) had no significant effect on cell proliferation compared to controls. Morphology of cells was unchanged after treatment with Bevacizumab and/or VEGF compared to controls. CONCLUSIONS: Bevacizumab was safe and not toxic to BCE cells at concentrations commonly used in clinical practice.
format Online
Article
Text
id pubmed-3247162
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-32471622012-01-04 Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells Rusovici, Raluca Sakhalkar, Monali Chalam, Kakarla V. Mol Vis Research Article PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and ameliorates neovascularization after intracameral administration. However, the safety of intracameral administration of Bevacizumab and dose–dependent toxicity on corneal endothelial cells has not been established. METHODS: Bovine corneal endothelial (BCE) cells were treated with VEGF (50 ng/ml) and/or Bevacizumab (0.1–2 mg/ml) for 72 h. Cell proliferation was measured with the water soluble tetrazolium salts (WST-1) assay. Morphological changes were recorded by bright-field microscopy of cells. Cytotoxicity in response to Bevacizumab was evaluated by trypan blue exclusion, as well as annexin V/propidium iodide (PI) staining. RESULTS: Bevacizumab was not cytotoxic at the concentrations tested and the percentage of Bevacizumab-treated cells staining positively for both PI and Annexin V was less than 1%. The anti-proliferative effects of Bevacizumab on BCE cells were dose-dependent; a dose of 1.5 mg/ml or 2 mg/ml produced a 33% (p=0.005) or 47% (p=0.001) decrease in cell proliferation compared to controls. Similar results were obtained in cells treated with a combination of Bevacizumab and VEGF. VEGF (50 ng/ml) had no significant effect on cell proliferation compared to controls. Morphology of cells was unchanged after treatment with Bevacizumab and/or VEGF compared to controls. CONCLUSIONS: Bevacizumab was safe and not toxic to BCE cells at concentrations commonly used in clinical practice. Molecular Vision 2011-12-20 /pmc/articles/PMC3247162/ /pubmed/22219629 Text en Copyright © 2011 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rusovici, Raluca
Sakhalkar, Monali
Chalam, Kakarla V.
Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
title Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
title_full Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
title_fullStr Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
title_full_unstemmed Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
title_short Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
title_sort evaluation of cytotoxicity of bevacizumab on vegf-enriched corneal endothelial cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/
https://www.ncbi.nlm.nih.gov/pubmed/22219629
work_keys_str_mv AT rusoviciraluca evaluationofcytotoxicityofbevacizumabonvegfenrichedcornealendothelialcells
AT sakhalkarmonali evaluationofcytotoxicityofbevacizumabonvegfenrichedcornealendothelialcells
AT chalamkakarlav evaluationofcytotoxicityofbevacizumabonvegfenrichedcornealendothelialcells